Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.
Where ChemoCentryx Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
